POTASSIUM CHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE (POTASSIUM CHLORIDE).
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. Approximately 90% is excreted in the urine, with the remainder in feces and sweat. Renal excretion is influenced by aldosterone. |
| Excretion | Primarily renal (90%) as potassium ion; minimal fecal (<10%) and sweat. |
| Half-life | Not applicable; potassium is an electrolyte regulated by homeostasis, not classic elimination half-life. Under normal renal function, serum half-life of administered potassium is approximately 2-4 hours due to rapid cellular uptake and renal excretion. |
| Protein binding | Minimal; <2% bound to plasma proteins. |
| Volume of Distribution | 0.5-0.7 L/kg; distributes primarily to intracellular compartment (98% of total body potassium is intracellular). |
| Bioavailability | Oral: 90-100% (well absorbed from gastrointestinal tract, subject to first-pass uptake by liver; bioavailability is near complete). |
| Onset of Action | IV: within seconds to minutes; oral: within 1-2 hours; depends on formulation (microencapsulated vs wax matrix). |
| Duration of Action | IV: 30-60 minutes; oral: 6-8 hours (sustained-release formulations). |
Oral: 40-100 mEq/day in divided doses; IV: up to 10-20 mEq/hour via central line, max 40 mEq/hour with continuous monitoring; not to exceed 200 mEq/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | eGFR >50: no adjustment; eGFR 10-50: reduce dose by 25-50%; eGFR <10: avoid or use with extreme caution, starting at 50% of usual dose. |
| Liver impairment | No specific adjustment required for Child-Pugh A, B, or C; monitor potassium levels closely due to risk of hyperkalemia. |
| Pediatric use | Oral: 1-3 mEq/kg/day in divided doses; IV: 0.25-0.5 mEq/kg/hour, max 1 mEq/kg/hour with cardiac monitoring; max daily dose 3 mEq/kg/day. |
| Geriatric use | Start at low end of adult dosing (e.g., 20 mEq/day) and titrate slowly; monitor renal function and potassium levels frequently due to decreased renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE (POTASSIUM CHLORIDE).
| Breastfeeding | Potassium is a normal constituent of breast milk. Potassium chloride supplementation at recommended doses is considered compatible with breastfeeding. Maternal milk-to-plasma (M/P) ratio is approximately 0.1-0.3, indicating low transfer. No adverse effects in nursing infants reported. |
| Teratogenic Risk | Potassium chloride is not teratogenic. There is no evidence of fetal harm from oral or intravenous administration at therapeutic doses, provided maternal potassium levels are maintained within normal range. No trimester-specific risks identified; however, maternal hypokalemia or hyperkalemia can adversely affect fetal outcomes (e.g., arrhythmias, growth restriction). |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Undiluted administration can result in fatal cardiac arrest. Also, potassium supplements should not be used in patients with hyperkalemia or conditions that predispose to hyperkalemia.
| Serious Effects |
["Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal impairment with oliguria or anuria","Uncontrolled Addison's disease","Acute dehydration","Concurrent use with potassium-sparing diuretics (e.g., spironolactone, eplerenone, amiloride, triamterene)","Solid oral forms in patients with conditions that delay GI transit or esophageal compression"]
| Precautions | ["Cardiac arrest if administered too rapidly or in concentrated form","Hyperkalemia risk especially in renal impairment, diabetes, or concurrent use of ACE inhibitors, ARBs, NSAIDs, or potassium-sparing diuretics","Gastrointestinal irritation with oral solid formulations; use with caution in patients with esophageal compression or delayed GI transit","Monitor serum potassium and ECG during parenteral therapy","Avoid potassium chloride in patients with severe burns, crush injuries, or other conditions that lead to rapid cellular breakdown"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels regularly, especially in women with renal impairment, preeclampsia, or on medications affecting potassium (e.g., ACE inhibitors, potassium-sparing diuretics). Assess renal function and urine output. Fetal monitoring not routinely required; consider fetal heart rate monitoring if maternal electrolyte disturbances occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium chloride is a normal physiological electrolyte and does not impair reproductive function when used therapeutically. |